Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings data on Monday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05), Fidelity Earnings reports.
Shares of NASDAQ:MBRX traded up $0.01 on Wednesday, hitting $1.22. 796,968 shares of the company traded hands, compared to its average volume of 2,600,803. Moleculin Biotech has a 52 week low of $0.78 and a 52 week high of $3.15. The company has a market capitalization of $42.29 million, a PE ratio of -2.39 and a beta of 2.26.
A number of brokerages have issued reports on MBRX. Zacks Investment Research lowered shares of Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 14th. Maxim Group restated a “buy” rating and issued a $3.00 price target on shares of Moleculin Biotech in a research report on Tuesday, February 5th. Finally, ValuEngine lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.